Calcium-sensing receptor polymorphism rs1042636 (Arg990Gly) affects the response to the
calcimimetic cinacalcet, used to treat hypercalcemia in secondary hyperparathyroidism …

Cinacalcet, a novel calcimimetic compound, is effective in reducing parathyroid hormone
(PTH) levels in approximately 70% of patients with secondary hyperparathyroidism …

Cinacalcet HCl is the first calcimimetic agent available for the therapy of secondary
hyperparathyroidism (sHPT) and palliative treatment of parathyroid carcinoma. It acts on the …

Although parathyroidectomy remains the only curative approach to most primary
hyperparathyroidism cases, medical treatment with cinacalcet HCl has been proven to be a …

Aims: Calcimimetics are effective in reducing parathyroid hormone (PTH) levels in patients
with secondary hyperparathyroidism, but variability in dose response has been noted. We …

Background Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …

Cinacalcet HCl, an allosteric modulator of the calcium-sensing receptor (CaR), has recently
been approved for the treatment of secondary hyperparathyroidism in patients with chronic …

Calcium sensing receptor (CASR) is a G-protein couple receptor which plays a key role in
calcium homeostasis in vertebrates. Its extracellular domain is sensitive to divalent cations …

Recently several studies in adolescent girls or premenopausal women have implicated the
calcium sensing receptor (CASR) gene A986S polymorphism in calcium and bone …

Background: Cinacalcet hydrochloride (cinacalcet), a calcimimetic, has been shown to
upregulate calcium-sensing receptor (CaSR) expression in parathyroid glands of rats with …